Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q2 2015 · 10-Q
Revenue$33.34M$33.34M+81.3% vs Q2 2014 Net Income-$26.88M-$26.88MN/M vs Q2 2014 EPS Diluted$0.02$0.02N/M vs Q2 2014 Gross Profit$5,391,000+51.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flowderived$8,938,000N/M Free Cash Flowderived$8,678,000N/M Margins · derivedGross margin16.2%−3.2 pt vs Q2 2014
Operating margin12.7%+94.0 pt vs Q2 2014
Net margin-80.6%+7.9 pt vs Q2 2014
ended Jun 30, 2015 · filed Aug 10, 2015 · 41 d after period end